Literature DB >> 9551401

Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction.

J Ma1, H Nishimura, A Fogo, V Kon, T Inagami, I Ichikawa.   

Abstract

We examined the role of angiotensin in renal remodeling that is specifically channeled through the angiotensin type 2 receptor (AT2 receptor). Previously, we observed that in mouse embryonic kidneys the AT2 mRNA is predominantly expressed in the mesenchyme. We therefore chose a model of unilateral ureteral obstruction, characterized by activation of the renin-angiotensin system, while fibrosis develops prominently within the renal interstitium. Male wild-type mice (Agtr2 -/Y) and mice null mutant for the AT2 gene (Agtr2 -/Y) were subjected to a complete unilateral ureteral ligation for 5 or 14 days. Obstructed kidneys of Agtr2 -/Y mice showed more severe interstitial fibrosis than those of Agtr2 +/Y mice, confirmed by increased collagen by point-counting on Masson trichrome stained sections, and increased alpha 1(I) collagen mRNA expression by Northern blot. Immunohistochemistry staining for PCNA (a marker of cell proliferation), F4/80 (a marker of macrophages), vimentin (a marker of fibroblasts), and alpha SMA (a marker of myofibroblasts) revealed that, while the two groups were comparable in the degree of cell proliferation and macrophage infiltration, fibroblasts/ myofibroblasts were present in a greater abundance in obstructed kidneys of Agtr2 -/Y mice than in Agtr2 +/Y at both 5 and 14 days after obstruction. Moreover, cells undergoing apoptosis were significantly less in Agtr2 -/Y than in Agtr2 +/Y. Thus, the AT2 receptor significantly impacts the remodeling process within renal interstitium, potentially by regulating the population of collagen-producing cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551401     DOI: 10.1111/j.1523-1755.1998.00893.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  44 in total

Review 1.  Role of ACE inhibitors in patients with diabetes mellitus.

Authors:  D J Cordonnier; P Zaoui; S Halimi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 3.  Local renin-angiotensin systems in the genitourinary tract.

Authors:  Craig Comiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-13       Impact factor: 3.000

Review 4.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

5.  The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.

Authors:  Bryna S M Chow; Christine Koulis; Pooja Krishnaswamy; Ulrike M Steckelings; Thomas Unger; Mark E Cooper; Karin A Jandeleit-Dahm; Terri J Allen
Journal:  Diabetologia       Date:  2016-05-11       Impact factor: 10.122

Review 6.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

7.  Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis.

Authors:  Masashi Nishida; Hidehiko Fujinaka; Taiji Matsusaka; James Price; Valentina Kon; Agnes B Fogo; Jeffrey M Davidson; MacRae F Linton; Sergio Fazio; Toshio Homma; Hiroaki Yoshida; Iekuni Ichikawa
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

8.  A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade.

Authors:  Hirokazu Okada; Tsutomu Inoue; Tomohiro Kikuta; Yusuke Watanabe; Yoshihiko Kanno; Shinichi Ban; Takeshi Sugaya; Masatsugu Horiuchi; Hiromichi Suzuki
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 9.  Obstructive nephropathy: insights from genetically engineered animals.

Authors:  Jean-Loup Bascands; Joost P Schanstra
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

10.  PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.

Authors:  Jee-Young Han; Ye-Ji Kim; Lucia Kim; Suk-Jin Choi; In-Suh Park; Joon-Mee Kim; Young Chae Chu; Dae-Ryong Cha
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.